Vaccine adjuvant

RNA and protein-based adjuvants, particularly cathelicidine linked to regulatory elements, address the poor immune response and adverse effects of conventional adjuvants, enhancing vaccine efficacy and safety.

JP2026516486APending Publication Date: 2026-05-25SEKIRAS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
SEKIRAS INC
Filing Date
2024-05-13
Publication Date
2026-05-25

AI Technical Summary

Technical Problem

Conventional vaccines often induce poor immune responses due to the use of impure pathogenic microorganisms or purified protein subunits, and existing adjuvants like aluminum hydroxide can cause adverse effects, necessitating the development of safer and more effective adjuvants.

Method used

The use of RNA and protein-based adjuvants, specifically cathelicidine or fragments thereof, linked to regulatory elements such as SG promoters and IRES, to enhance immunogenicity and antigen delivery.

Benefits of technology

Enhances immune response magnitude and function, reduces antigen dose requirements, and minimizes adverse effects, making vaccines more effective and safer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026516486000001
    Figure 2026516486000001
  • Figure 2026516486000002
    Figure 2026516486000002
  • Figure 2026516486000003
    Figure 2026516486000003
Patent Text Reader

Abstract

This disclosure relates to antigen-encoding RNAs and other polynucleotides that can be used in vaccine compositions. In some examples, the RNA or polynucleotide also encodes an adjuvant, such as cathelicidine or a fragment thereof. This disclosure also relates to the use of RNA, polynucleotides, or compositions in methods for inducing an immune response in a subject.
Need to check novelty before this filing date? Find Prior Art